Physician profile
Breanne M Roche
NPI 1699174227
$58,401.97
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $8,551 · 2023: $11K · 2024: $8,710 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $2,422 · Consulting Fee: $2,275 · Travel and Lodging: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,523.50 |
| Food and Beverage | $2,422.07 |
| Consulting Fee | $2,275.00 |
| Travel and Lodging | $950.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34,354.59 | 2022-2025 | Koselugo |
| Btg International INC. | $20,106.06 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,269.37 | 2021 | |
| Amgen INC. | $825.11 | 2021-2025 | Blincyto, Blincyto |
| Jazz Pharmaceuticals INC. | $428.08 | 2021-2025 | |
| Genzyme Corporation | $344.71 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.93 | 2022-2024 | |
| Y-Mabs Therapeutics, INC. | $217.42 | 2023-2025 | Danyelza |
| Day One Biopharmaceuticals | $124.99 | 2024 | Ojemda |
| Uswm, LLC | $123.45 | 2025 | Iwilfin |
| Servier Pharmaceuticals LLC | $121.14 | 2022 | |
| Emmaus Medical, INC. | $72.85 | 2024 | Endari |
| Novo Nordisk INC | $52.65 | 2022-2025 | Alhemo |
| Csl Behring | $37.95 | 2022-2025 | Hemgenix |
| Novartis Pharmaceuticals Corporation | $35.93 | 2023-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $23.69 | 2021 | |
| Springworks Therapeutics, INC. | $21.42 | 2025 | Gomekli |
| Chiesi USA, INC. | $14.63 | 2025 | Ferriprox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanne Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.